Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/644"
| Predicate | Value (sorted: default) |
|---|
| rdfs:label |
|
| rdf:type |
|
| ?:Evidence_enzyme_system |
|
| ?:Evidence_type |
|
| ?:content |
"Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative. In humans, unchanged citalopram is the predominant compound in plasma. At steady state, the concentrations of citalopram's metabolites, DCT and DDCT, in plasma are approximately one-half and one-tenth, respectively, that of the parent drug. In vitro studies show that citalopram is at least 8 times more potent than its metabolites in the inhibition of serotonin reuptake, suggesting that the metabolites evaluated do not likely contribute significantly to the antidepressant actions of citalopram."
|
| dc:creator |
|
| dc:date |
|
| rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ citalopram_has_metabolite_didemethylcitalopram, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1427 }
Context graph
